MedTrace Logo

EAP for the Treatment of Glioblastoma With PVSRIPO

NCT04599647 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-06-29

No results posted yet for this study

Summary

This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.

Conditions

Interventions

BIOLOGICAL

PVSRIPO

PVSRIPO (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).

Sponsors & Collaborators

  • Istari Oncology, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04599647 on ClinicalTrials.gov